Findings of the RxPONDER clinical trial, a study led by Dr. Kevin Kalinsky of the Winship Cancer Institute at Emory University in Atlanta, GA, USA were recently published in the New England Journal of Medicine. RxPONDER (a clinical trial RX for positive node, endocrine responsive breast cancer), "randomly assigned participants [~5000 women] with hormone receptor-positive, HER2-negative breast cancer, 1 to 3 positive axillary lymph nodes (nodal stage N1), and a recurrence score of 25 or lower to endocrine therapy only or to chemoendocrine therapy." After a period of 5 years, the study determined that the relative chemotherapy benefit did not increase as the recurrence score increased.
To read more about this trial, click here.
Study mentioned: Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. NEJM; Published online 1 December 2021. DOI: 10.1056/NEJMoa2108873
No comments:
Post a Comment